标题
New drugs for NASH
作者
关键词
-
出版物
LIVER INTERNATIONAL
Volume 41, Issue S1, Pages 112-118
出版商
Wiley
发表日期
2021-06-22
DOI
10.1111/liv.14844
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- New drugs for non‐alcoholic steatohepatitis
- (2020) Ana‐Carolina Cardoso et al. LIVER INTERNATIONAL
- Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
- (2020) Beth A. Davison et al. JOURNAL OF HEPATOLOGY
- Selective Thyroid Hormone Receptor-Beta (TRβ) Agonists: New Perspectives for the Treatment of Metabolic and Neurodegenerative Disorders
- (2020) Federica Saponaro et al. Frontiers in Medicine
- NGM 282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis
- (2019) Stephen A. Harrison et al. HEPATOLOGY
- Novel MRI assessment of treatment response in HIV ‐associated NAFLD : a randomized trial of an SCD 1 inhibitor ( ARRIVE Trial)
- (2019) Veeral H. Ajmera et al. HEPATOLOGY
- REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis
- (2019) Vlad Ratziu et al. Contemporary Clinical Trials
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
- (2019) Marcos Pedrosa et al. Contemporary Clinical Trials
- Development of new drugs for the treatment of nonalcoholic steatohepatitis
- (2019) Jie Ting Tang et al. Journal of Digestive Diseases
- Non-alcoholic Steatohepatitis is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
- (2018) Zobair Younossi et al. Clinical Gastroenterology and Hepatology
- MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis
- (2018) Jerry R. Colca et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Projected increase in obesity and non-alcoholic-steatohepatitis-related liver transplantation waitlist additions in the United States
- (2018) Neehar D. Parikh et al. HEPATOLOGY
- NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Stephen A Harrison et al. LANCET
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
- (2017) Rohit Loomba et al. HEPATOLOGY
- Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
- (2017) Chris Estes et al. HEPATOLOGY
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
- (2017) Melanie Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
- (2017) David C. Tully et al. JOURNAL OF MEDICINAL CHEMISTRY
- New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
- (2017) Manan Jhaveri et al. Therapeutics and Clinical Risk Management
- Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design
- (2016) Scott Friedman et al. Contemporary Clinical Trials
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
- (2016) Eric Lefebvre et al. PLoS One
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Thyroid hormone receptor-β agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways
- (2013) Daniel F. Vatner et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
- (2011) G. Vernon et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Fatty Acid Bile Acid Conjugate Inhibits Hepatic Stearoyl Coenzyme A Desaturase and Is Non-atherogenic
- (2010) Alicia Leikin-Frenkel et al. ARCHIVES OF MEDICAL RESEARCH
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started